Longevity Novo Nordisk’s Alzheimer’s GLP-1 gamble failsBy adminNovember 26, 20250 Long shot Phase 3 trial finds semaglutide did not deliver a statistically significant reduction in Alzheimer’s progression. Pharma giant Novo…
Microbiome Novo Nordisk’s GLP-1 Drug Fails to Improve Alzheimer’s SymptomsBy adminNovember 25, 20250 Credit: Juan Gaertner/Science Photo Library/Getty Images The results from two Phase III trials announced this week show Novo Nordisk’s GLP-1…
DNA & Genetics Analysts See Pain, and Necessity, in Novo Nordisk’s 9,000 LayoffsBy adminSeptember 14, 20250 Novo Nordisk (NASDAQ Copenhagen: NOVO-B) inflicted much pain—and much-needed pain—on the company when president and CEO Maziar (Mike) Doustdar announced…
